Published in Mol Ther on January 05, 2010
Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer (2010) 2.70
In tumors Salmonella migrate away from vasculature toward the transition zone and induce apoptosis. Cancer Gene Ther (2011) 1.15
Motility is critical for effective distribution and accumulation of bacteria in tumor tissue. Integr Biol (Camb) (2011) 1.02
Engineering of bacteria for the visualization of targeted delivery of a cytolytic anticancer agent. Mol Ther (2013) 0.99
Targeted deletion of the ara operon of Salmonella typhimurium enhances L-arabinose accumulation and drives PBAD-promoted expression of anti-cancer toxins and imaging agents. Cell Cycle (2014) 0.93
Bacterial delivery of Staphylococcus aureus α-hemolysin causes regression and necrosis in murine tumors. Mol Ther (2014) 0.90
New paradigm for tumor theranostic methodology using bacteria-based microrobot. Sci Rep (2013) 0.89
Potent and tumor specific: arming bacteria with therapeutic proteins. Ther Deliv (2015) 0.86
A novel balanced-lethal host-vector system based on glmS. PLoS One (2013) 0.84
Engineering and visualization of bacteria for targeting infarcted myocardium. Mol Ther (2011) 0.84
Salmonella typhimurium Suppresses Tumor Growth via the Pro-Inflammatory Cytokine Interleukin-1β. Theranostics (2015) 0.82
Engineering Escherichia coli for light-activated cytolysis of mammalian cells. ACS Synth Biol (2014) 0.77
Tumor-targeting bacterial therapy: A potential treatment for oral cancer (Review). Oncol Lett (2014) 0.76
Impediments to enhancement of CPT-11 anticancer activity by E. coli directed beta-glucuronidase therapy. PLoS One (2015) 0.75
Radiotherapy combined with an engineered Salmonella typhimurium inhibits tumor growth in a mouse model of colon cancer. Exp Anim (2016) 0.75
Targeted Cancer Therapy Using Engineered Salmonella typhimurium. Chonnam Med J (2016) 0.75
Three-dimensional tumor spheroids for in vitro analysis of bacteria as gene delivery vectors in tumor therapy. Microb Cell Fact (2015) 0.75
Salmonella-Mediated Cancer Therapy: Roles and Potential. Nucl Med Mol Imaging (2016) 0.75
One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A (2000) 96.90
The complete genome sequence of Escherichia coli K-12. Science (1997) 84.27
Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat Biotechnol (1999) 3.97
Vesicle-mediated export and assembly of pore-forming oligomers of the enterobacterial ClyA cytotoxin. Cell (2003) 3.88
Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol (2004) 3.36
The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res (1999) 2.91
Cloning and characterization of the asd gene of Salmonella typhimurium: use in stable maintenance of recombinant plasmids in Salmonella vaccine strains. Gene (1990) 2.80
Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci U S A (2005) 2.76
Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci U S A (2001) 2.62
Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res (2006) 2.51
Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer. Proc Natl Acad Sci U S A (2007) 2.46
Functional gene transfer from intracellular bacteria to mammalian cells. Nat Biotechnol (1998) 2.30
Systemic targeting of primary bone tumor and lung metastasis of high-grade osteosarcoma in nude mice with a tumor-selective strain of Salmonella typhimurium. Cell Cycle (2009) 2.28
Immune responses to recombinant pneumococcal PspA antigen delivered by live attenuated Salmonella enterica serovar typhimurium vaccine. Infect Immun (2002) 2.25
Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res (2003) 2.24
Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst (1997) 2.01
Bacteria-mediated delivery of nanoparticles and cargo into cells. Nat Nanotechnol (2007) 1.83
Efficacy of a genetically-modified Salmonella typhimurium in an orthotopic human pancreatic cancer in nude mice. Anticancer Res (2009) 1.81
Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist (2002) 1.78
Bacteria as tumour-targeting vectors. Lancet Oncol (2003) 1.78
Monotherapy with a tumor-targeting mutant of S. typhimurium inhibits liver metastasis in a mouse model of pancreatic cancer. J Surg Res (2009) 1.76
Cancer metastasis directly eradicated by targeted therapy with a modified Salmonella typhimurium. J Cell Biochem (2009) 1.73
Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci U S A (2004) 1.63
Short hairpin RNA-expressing bacteria elicit RNA interference in mammals. Nat Biotechnol (2006) 1.61
Biological gene delivery vehicles: beyond viral vectors. Mol Ther (2009) 1.43
ppGpp-dependent stationary phase induction of genes on Salmonella pathogenicity island 1. J Biol Chem (2004) 1.41
Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther (2003) 1.40
Cytocidal and apoptotic effects of the ClyA protein from Escherichia coli on primary and cultured monocytes and macrophages. Infect Immun (2000) 1.39
Colonization of experimental murine breast tumours by Escherichia coli K-12 significantly alters the tumour microenvironment. Cell Microbiol (2008) 1.37
Molecular analysis of the cytolytic protein ClyA (SheA) from Escherichia coli. Mol Microbiol (1999) 1.37
Characterization of a pore-forming cytotoxin expressed by Salmonella enterica serovars typhi and paratyphi A. Infect Immun (2002) 1.36
Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. Proc Natl Acad Sci U S A (2007) 1.24
Quantitative bioluminescence imaging of tumor-targeting bacteria in living animals. Nat Protoc (2008) 1.22
Bacterial delivery of a novel cytolysin to hypoxic areas of solid tumors. Gene Ther (2009) 1.17
Noninvasive real-time imaging of tumors and metastases using tumor-targeting light-emitting Escherichia coli. Mol Imaging Biol (2007) 1.16
Recombinant avirulent Salmonella vaccine strains with stable maintenance and high level expression of cloned genes in vivo. Immunol Invest (1989) 1.15
Salmonella promoters preferentially activated inside tumors. Cancer Res (2008) 1.11
Whole-body imaging of bacterial infection and antibiotic response. Nat Protoc (2006) 1.04
Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth. Cancer Immunol Immunother (2008) 1.01
Inhibition of tumor growth using salmonella expressing Fas ligand. J Natl Cancer Inst (2008) 0.99
Recent advances in the use of radiosensitizing nucleosides. Semin Radiat Oncol (2001) 0.96
CDX-2 homeobox gene expression in human gastric carcinoma and precursor lesions. J Gastroenterol Hepatol (2006) 0.95
The lux genes of the luminous bacterial symbiont, Photobacterium leiognathi, of the ponyfish. Nucleotide sequence, difference in gene organization, and high expression in mutant Escherichia coli. Eur J Biochem (1991) 0.94
IL-18-producing Salmonella inhibit tumor growth. Cancer Gene Ther (2008) 0.89
Prospects for viral-based strategies enhancing the anti-tumor effects of ionizing radiation. Semin Radiat Oncol (2001) 0.84
Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood (2006) 3.33
Characterization and pathogenic significance of Vibrio vulnificus antigens preferentially expressed in septicemic patients. Infect Immun (2003) 2.69
Molecular imaging of cardiac cell transplantation in living animals using optical bioluminescence and positron emission tomography. Circulation (2003) 2.37
Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer. Eur J Nucl Med Mol Imaging (2012) 2.04
Regulation of Vibrio vulnificus virulence by the LuxS quorum-sensing system. Mol Microbiol (2003) 1.76
Vibrio vulnificus RTX toxin kills host cells only after contact of the bacteria with host cells. Cell Microbiol (2007) 1.64
A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. Infect Immun (2006) 1.63
Regulation of Msx genes by a Bmp gradient is essential for neural crest specification. Development (2003) 1.54
Fluorescent protein expression driven by her4 regulatory elements reveals the spatiotemporal pattern of Notch signaling in the nervous system of zebrafish embryos. Dev Biol (2006) 1.52
Integrative genome-scale metabolic analysis of Vibrio vulnificus for drug targeting and discovery. Mol Syst Biol (2011) 1.50
ppGpp-dependent stationary phase induction of genes on Salmonella pathogenicity island 1. J Biol Chem (2004) 1.41
DNA looping-mediated repression by histone-like protein H-NS: specific requirement of Esigma70 as a cofactor for looping. Genes Dev (2005) 1.38
Genetically engineered Salmonella typhimurium as an imageable therapeutic probe for cancer. Cancer Res (2009) 1.38
Molecular imaging of the kinetics of vascular endothelial growth factor gene expression in ischemic myocardium. Circulation (2004) 1.33
Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease. Blood (2006) 1.31
Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. Eur J Cancer (2011) 1.23
Quantitative bioluminescence imaging of tumor-targeting bacteria in living animals. Nat Protoc (2008) 1.22
PIG-V involved in transferring the second mannose in glycosylphosphatidylinositol. J Biol Chem (2004) 1.22
Incidental focal F-18 FDG accumulation in lung parenchyma without abnormal CT findings. Ann Nucl Med (2009) 1.19
Noninvasive real-time imaging of tumors and metastases using tumor-targeting light-emitting Escherichia coli. Mol Imaging Biol (2007) 1.16
The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas. Neuropathology (2011) 1.16
A multicenter retrospective cohort study of practice patterns and clinical outcome on radiotherapy for hepatocellular carcinoma in Korea. Liver Int (2008) 1.16
Impact of medication discontinuation on increased intestinal FDG accumulation in diabetic patients treated with metformin. AJR Am J Roentgenol (2010) 1.11
Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats. Circ J (2010) 1.09
Comparison of [14C]FMAU, [3H]FEAU, [14C]FIAU, and [3H]PCV for monitoring reporter gene expression of wild type and mutant herpes simplex virus type 1 thymidine kinase in cell culture. Mol Imaging Biol (2006) 1.07
A metazoan ortholog of SpoT hydrolyzes ppGpp and functions in starvation responses. Nat Struct Mol Biol (2010) 1.06
Casein kinase-2α1 induces hypertrophic response by phosphorylation of histone deacetylase 2 S394 and its activation in the heart. Circulation (2011) 1.06
Clinical efficacy and prediction of response to granulocyte transfusion therapy for patients with neutropenia-related infections. Haematologica (2004) 1.05
Iodine-131 uptake in focal bronchiectasis mimicking metastatic thyroid cancer. Clin Nucl Med (2003) 1.04
In vivo bioluminescence imaging of cord blood derived mesenchymal stem cell transplantation into rat myocardium. Ann Nucl Med (2006) 1.03
Salmonella enterica serovar gallinarum requires ppGpp for internalization and survival in animal cells. J Bacteriol (2008) 1.02
Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy. ACS Nano (2014) 1.02
Immunological characterization of glioblastoma cells for immunotherapy. Anticancer Res (2013) 1.01
The prognostic significance of tumor human papillomavirus status for patients with anal squamous cell carcinoma treated with combined chemoradiotherapy. Int J Cancer (2011) 1.00
Tcf3 inhibits spinal cord neurogenesis by regulating sox4a expression. Development (2009) 1.00
Protective effect of polygoni cuspidati radix and emodin on Vibrio vulnificus cytotoxicity and infection. J Microbiol (2008) 1.00
Immune response induced by Salmonella typhimurium defective in ppGpp synthesis. Vaccine (2005) 0.99
PIG-W is critical for inositol acylation but not for flipping of glycosylphosphatidylinositol-anchor. Mol Biol Cell (2003) 0.99
Estrogen-related receptor γ (ERRγ) is a novel transcriptional regulator of phosphatidic acid phosphatase, LIPIN1, and inhibits hepatic insulin signaling. J Biol Chem (2011) 0.99
Engineering of bacteria for the visualization of targeted delivery of a cytolytic anticancer agent. Mol Ther (2013) 0.99
Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study. Ann Hematol (2014) 0.98
Genetic diversity of porcine sapoviruses. Vet Microbiol (2007) 0.98
A bacterial RTX toxin causes programmed necrotic cell death through calcium-mediated mitochondrial dysfunction. J Infect Dis (2012) 0.97
Preoperative short-course concurrent chemoradiation therapy followed by delayed surgery for locally advanced rectal cancer: a phase 2 multicenter study (KROG 10-01). Int J Radiat Oncol Biol Phys (2012) 0.97
Nrf2, a regulator of the proteasome, controls self-renewal and pluripotency in human embryonic stem cells. Stem Cells (2014) 0.96
RtxA1-induced expression of the small GTPase Rac2 plays a key role in the pathogenicity of Vibrio vulnificus. J Infect Dis (2010) 0.96
Effects of urinary trypsin inhibitor on lipopolysaccharide-induced acute lung injury in rabbits. Inflammation (2012) 0.95
Caenorhabditis elegans as a simple model host for Vibrio vulnificus infection. Biochem Biophys Res Commun (2006) 0.95
Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era. Ann Hematol (2012) 0.95
Asialoglycoprotein receptor targeted gene delivery using galactosylated polyethylenimine-graft-poly(ethylene glycol): in vitro and in vivo studies. J Control Release (2005) 0.95
The glycan core of GPI-anchored proteins modulates aerolysin binding but is not sufficient: the polypeptide moiety is required for the toxin-receptor interaction. FEBS Lett (2002) 0.94
Inappropriateness of quinolone in scrub typhus treatment due to gyrA mutation in Orientia tsutsugamushi Boryong strain. J Korean Med Sci (2013) 0.94
Evaluation of a mitochondrial voltage sensor, (18F-fluoropentyl)triphenylphosphonium cation, in a rat myocardial infarction model. J Nucl Med (2012) 0.94
Targeted deletion of the ara operon of Salmonella typhimurium enhances L-arabinose accumulation and drives PBAD-promoted expression of anti-cancer toxins and imaging agents. Cell Cycle (2014) 0.93
Antitumor activity of novel indirubin derivatives in rat tumor model. Clin Cancer Res (2007) 0.93
High performance pseudocapacitor based on 2D layered metal chalcogenide nanocrystals. Nano Lett (2015) 0.93
Selective fluorescent chemosensor for the bacterial alarmone (p)ppGpp. J Am Chem Soc (2008) 0.93
Synthesis of [18F]-labeled (6-fluorohexyl)triphenylphosphonium cation as a potential agent for myocardial imaging using positron emission tomography. Bioconjug Chem (2012) 0.93
Production of Vibrio vulnificus hemolysin in vivo and its pathogenic significance. Biochem Biophys Res Commun (2004) 0.92
The initial enzyme for glycosylphosphatidylinositol biosynthesis requires PIG-Y, a seventh component. Mol Biol Cell (2005) 0.92
Inflammatory pseudotumours resembling multiple hepatic metastases and their complete regression, as revealed by 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging (2009) 0.92
GPI7 is the second partner of PIG-F and involved in modification of glycosylphosphatidylinositol. J Biol Chem (2005) 0.92
Role of galectin-1 in migration and invasion of human glioblastoma multiforme cell lines. J Neurosurg (2008) 0.92
Expression of e-cadherin and catenins in early gastric cancer. J Clin Gastroenterol (2002) 0.91
Regulation of acetylation of histone deacetylase 2 by p300/CBP-associated factor/histone deacetylase 5 in the development of cardiac hypertrophy. Circ Res (2014) 0.91
Mobility of intradural extramedullary schwannoma at spine : report of three cases with literature review. J Korean Neurosurg Soc (2010) 0.91
Use of gabapentin in the prevention of taxane-induced arthralgias and myalgias. J Clin Oncol (2004) 0.91
Role of gut microbiota in graft-versus-host disease. Leuk Lymphoma (2011) 0.90
Epstein-Barr virus infected natural killer cell lymphoma in a patient with hypersensitivity to mosquito bite. J Infect (2005) 0.90
Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist. Exp Mol Med (2010) 0.90
Difference in agr dysfunction and reduced vancomycin susceptibility between MRSA bacteremia involving SCCmec types IV/IVa and I-III. PLoS One (2012) 0.90
Mammalian PIG-X and yeast Pbn1p are the essential components of glycosylphosphatidylinositol-mannosyltransferase I. Mol Biol Cell (2005) 0.90
New paradigm for tumor theranostic methodology using bacteria-based microrobot. Sci Rep (2013) 0.89
Concurrent chemoradiotherapy with cisplatin and fluorouracil for locally advanced hypopharyngeal carcinoma. Acta Otolaryngol (2008) 0.89
A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer. Cancer Chemother Pharmacol (2012) 0.89
Factors influencing preferential utilization of RNA polymerase containing sigma-38 in stationary-phase gene expression in Escherichia coli. J Microbiol (2004) 0.89